MADDEN SECURITIES Corp purchased a new stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,510 shares of the medical research company’s stock, valued at approximately $612,000.

Several other institutional investors also recently bought and sold shares of CRL. Norges Bank bought a new stake in shares of Charles River Laboratories Intl. during the fourth quarter valued at approximately $78,648,000. Massachusetts Financial Services Co. MA boosted its holdings in Charles River Laboratories Intl. by 149.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 588,931 shares of the medical research company’s stock valued at $74,329,000 after purchasing an additional 352,637 shares during the last quarter. Iridian Asset Management LLC CT boosted its holdings in Charles River Laboratories Intl. by 126.3% in the first quarter. Iridian Asset Management LLC CT now owns 477,157 shares of the medical research company’s stock valued at $60,222,000 after purchasing an additional 266,270 shares during the last quarter. Sandler Capital Management purchased a new stake in Charles River Laboratories Intl. in the first quarter valued at $22,882,000. Finally, Confluence Investment Management LLC purchased a new stake in Charles River Laboratories Intl. in the first quarter valued at $20,997,000. 93.25% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Birgit Girshick sold 780 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $165.74, for a total value of $129,277.20. Following the completion of the sale, the vice president now owns 21,837 shares of the company’s stock, valued at approximately $3,619,264.38. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert J. Bertolini sold 3,530 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $174.58, for a total transaction of $616,267.40. Following the completion of the sale, the director now directly owns 32,664 shares of the company’s stock, valued at approximately $5,702,481.12. The disclosure for this sale can be found here. In the last three months, insiders sold 22,697 shares of company stock valued at $3,744,212. Corporate insiders own 1.90% of the company’s stock.

CRL stock traded up $6.94 during mid-day trading on Tuesday, reaching $187.45. The company’s stock had a trading volume of 378,159 shares, compared to its average volume of 431,847. The stock has a market cap of $8.93 billion, a PE ratio of 36.60, a P/E/G ratio of 1.88 and a beta of 1.19. The company has a current ratio of 1.75, a quick ratio of 1.51 and a debt-to-equity ratio of 1.49. Charles River Laboratories Intl. Inc has a fifty-two week low of $95.58 and a fifty-two week high of $189.85. The company’s 50 day moving average is $177.90 and its two-hundred day moving average is $156.64.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $1.84 EPS for the quarter, beating the Zacks’ consensus estimate of $1.46 by $0.38. Charles River Laboratories Intl. had a net margin of 9.09% and a return on equity of 22.69%. The company had revenue of $707.06 million during the quarter, compared to the consensus estimate of $692.11 million. During the same quarter in the prior year, the firm earned $1.40 EPS. Charles River Laboratories Intl.’s quarterly revenue was up 17.0% on a year-over-year basis. On average, analysts forecast that Charles River Laboratories Intl. Inc will post 6.88 earnings per share for the current fiscal year.

Several equities research analysts have commented on CRL shares. Barclays lowered their price target on shares of Charles River Laboratories Intl. from $170.00 to $154.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Credit Suisse Group lowered their price target on shares of Charles River Laboratories Intl. from $162.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Bank of America raised shares of Charles River Laboratories Intl. from a “neutral” rating to a “buy” rating and set a $192.00 price target on the stock in a report on Wednesday, July 1st. Citigroup upped their price objective on shares of Charles River Laboratories Intl. from $165.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Argus upped their price objective on shares of Charles River Laboratories Intl. from $150.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average target price of $177.89.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Systematic Risk

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.